Metastatic Clear-Cell RCC After IO-Based First-Line Therapy: Choosing the Next Treatment

Authored by Natalia Gandur, published on 2026-05-27 22:45:35.0

This algorithm guides next-line systemic therapy selection for patients with metastatic clear-cell renal cell carcinoma (ccRCC) who progress after first-line IO/TKI or IO/IO therapy. The algorithm is not intended to duplicate first-line metastatic RCC treatment selection. It focuses on one practical sequencing question: After progression on IO-based first-line therapy, what should be the next treatment?The key principle is that routine immunotherapy rechallenge should not be the default. EAU notes that sequencing ICI with atezolizumab in CONTACT-03 did not improve ORR, PFS, or OS over single-agent TKI, and that tivozanib plus nivolumab in TiNivo-2 did not improve outcomes over tivozanib alone.

METASTATIC CLEAR-CELL RCC AFTER IO-BASED FIRST-LINE THERAPY => CONFIRM PROGRESSION

Radiographic or clinical progression; Clear-cell histology/clear-cell component; Prior first-line IO-based regimen; Reassess key clinical factors (see below)
- REASSESS KEY CLINICAL FACTORS
  
  Prior regimen & TKI exposure; Disease tempo & symptoms; Sites of disease (liver, brain, etc.); ECOG PS & frailty; Renal function & comorbidities; Prior irAEs & TKI toxicities; Clinical trial availability; Patient preference & logistics
  - PRIOR FIRST-LINE REGIMEN?
    
    Key principles: Individualize therapy based on prior treatment, disease biology, patient factors, and goals of care. Clinical trials should be considered early and throughout the disease course. Treatment goals: Prolong survival; Control symptoms; Preserve quality of life; Minimize toxicity; Align with patient values
    - PRIOR IO/IO THERAPY (e.g., nivolumab + ipilimumab)
      - Generally VEGF-TKI naive
        
        Start VEGF-TKI–based therapy
        
        TYPICALLY PREFERRED: CABOZANTINIB
        
        Cabozantinib is one of the most evidence-supported standards after IO failure, especially after IO/IO, and especially for rapidly progressive disease, bone metastases, or aggressive biology. But it is not universally preferred in all scenarios. Alternative VEGF-TKIs based on patient factors, access, comorbidities and toxicity profile. Preferred VEGF-TKI options: Cabozantinib favored for aggressive disease/bone metastases Axitinib favored if tolerability/flexibility important Tivozanib useful later-line or after multiple prior TKIs
    - PRIOR IO/TKI THERAPY
      - WHICH TKI WAS USED IN FIRST LINE?
        
        AXITINIB
        
        PREFERRED: CABOZANTINIB
        
        Avoid repeating axitinib
        
        CABOZANTINIB
        
        CONSIDER: Lenvatinib + everolimus; Tivozanib; Belzutifan (later line); Clinical trial
        
        Avoid cabozantinib rechallenge
        
        LENVATINIB
        
        CONSIDER: Cabozantinib (if not previously used); Tivozanib; Belzutifan (later line); Clinical trial
KEY MODIFIERS (APPLY TO BOTH IO/IO and IO/TKI PATHWAYS)

Need for rapid disease control VEGF-TKI toxicity limits options Brain metastases Poor performance status/frailty Prior immune-related adverse events Clinical trial available?
ROUTINE IO RECHALLENGE IS NOT RECOMMENDED

Evidence against routine IO rechallenge: CONTACT-03 (atezolizumab+cabozantinib vs cabozantinib alone) no improvement TiNivo-2 (tivozanib+nivolumab vs tivozanib alone) no improvement. Consider IO rechallenge only in: clinical trial; prior IO stopped for toxicity rather than progression; very selected situations with expert multidisciplinary input.

tos privacy